Please ensure Javascript is enabled for purposes of website accessibility

Why BioCryst Pharmaceuticals Stock Is Popping Today

By Prosper Junior Bakiny - Apr 14, 2021 at 3:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors cheered good news out of Japan for the company's lead product.

What happened?

Shares of BioCryst Pharmaceuticals (BCRX 2.46%) are trading higher on Wednesday following the company's announcement of positive news regarding its hereditary angioedema (HAE) treatment, Orladeyo. The company's stock was up by 6.2% as of 3:33 p.m. EDT, after rising by as much as 9.8% earlier in the trading session. 

So what

Back in January, oral once-daily Orladeyo was approved in Japan for prophylactic treatment of HAE. Today, BioCryst Pharma announced that the Japanese National Health Insurance System (NHI) has approved the addition of Orladeyo to its drug price list starting on April 21. Torii Pharmaceutical, a drugmaker headquartered in Japan, owns the commercial rights to Orladeyo in the country. 

Doctor giving a thumbs up.

Image source: Getty Images.

Torii is set to launch Orladeyo in Japan once the NHI drug price listing kicks in. Importantly, this development triggers a $15 million milestone payment from Torii to BioCryst. BioCryst is also entitled to receive royalties ranging from 20% to 40% of Orladeyo's net sales in Japan. These factors explain why investors cheered this news, especially considering Orladeyo is the only prophylactic treatment for HAE approved in Japan.

Now what

BioCryst Pharma and its shareholders have more to look forward to regarding Orladeyo. The healthcare company has already filed for approval of this treatment in the EU, and it expects an answer from regulators during the second quarter. If Orladeyo earns regulatory approval in Europe, BioCryst Pharma's shares will likely rise on the news. In short, investors should pay close attention to BioCryst over the next few weeks.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioCryst Pharmaceuticals, Inc. Stock Quote
BioCryst Pharmaceuticals, Inc.
$10.84 (2.46%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.